| Year |
Citation |
Score |
| 2013 |
Ellsworth KA, Eckloff BW, Li L, Moon I, Fridley BL, Jenkins GD, Carlson E, Brisbin A, Abo R, Bamlet W, Petersen G, Wieben ED, Wang L. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. Plos One. 8: e70216. PMID 23936393 DOI: 10.1371/Journal.Pone.0070216 |
0.498 |
|
| 2013 |
Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenetics and Genomics. 23: 156-66. PMID 23324805 DOI: 10.1097/Fpc.0B013E32835Dc133 |
0.545 |
|
| 2013 |
Ellsworth KA, Eckloff BW, Li L, Moon I, Fridley BL, Jenkins GD, Carlson E, Brisbin A, Abo R, Bamlet W, Petersen G, Wieben ED, Wang L. Abstract 2209: Contribution ofFKBP5genetic variation to gemcitabine treatment and survival in pancreatic cancer. Cancer Research. 73: 2209-2209. DOI: 10.1158/1538-7445.Am2013-2209 |
0.576 |
|
| 2012 |
Brisbin A, Jenkins GD, Ellsworth KA, Wang L, Fridley BL. Localization of association signal from risk and protective variants in sequencing studies. Frontiers in Genetics. 3: 173. PMID 22973297 DOI: 10.3389/Fgene.2012.00173 |
0.443 |
|
| 2010 |
Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Research. 70: 319-28. PMID 20048079 DOI: 10.1158/0008-5472.Can-09-3224 |
0.537 |
|
| Show low-probability matches. |